Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials

CONCLUSION: Meta-analysis reveals that baricitinib 4 mg is beneficial for treating active SLE in terms of a reduction of ≥ 4 points from baseline in SLEDAI-2K score and SLEDAI-2K remission of arthritis or rash. However, the higher frequency of SAEs and serious infections was observed in the group receiving baricitinib 4 mg.PMID:37853751 | DOI:10.1177/09612033231208842

Source: Lupus - October 19, 2023 Category: Rheumatology Authors: Young Ho Lee Gwan Gyu Song Source Type: research